We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
123 hedge funds and large institutions have $170M invested in Lineage Cell Therapeutics in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 29 increasing their positions, 28 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
57% more call options, than puts
Call options by funds: $180K | Put options by funds: $115K
14% more capital invested
Capital invested by funds: $149M → $170M (+$21.2M)
10% more funds holding
Funds holding: 112 → 123 (+11)
5.63% more ownership
Funds ownership: 38.5% → 44.14% (+5.6%)
4% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
123
Holders Change
+11
Holders Change %
+9.82%
% of All Funds
1.5%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
25
Increased
29
Reduced
28
Closed
12
Calls
$180K
Puts
$115K
Net Calls
+$65K
Net Calls Change
-$500K
Top Buyers
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$11.8M |
| 2 |
BlackRock
New York
|
+$2.78M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.36M |
| 4 |
Goldman Sachs
New York
|
+$2.24M |
| 5 |
Morgan Stanley
New York
|
+$1.72M |
